Ratings by TD Cowen (Tara Bancroft)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 3/6/2026 | Day One Biopharmaceuticals | DAWN | Downgrade | Hold (Buy) |
12.78 (21.20) |
65.88% | Details | |
| 2/26/2026 | Lantheus Holdings | LNTH | Maintain | Buy (N/A) |
|
Details | ||
| 2/26/2026 | Protagonist Therapeutics | PTGX | Maintain | (N/A) |
|
Details | ||
| 2/25/2026 | Vaxcyte | PCVX | Maintain | (N/A) |
|
Details | ||
| 2/6/2026 | Nanobiotix S.A | NBTX | New Coverage | Buy (N/A) |
21.03 (33.99) |
61.63% | Details | |
| 1/29/2026 | Day One Biopharmaceuticals | DAWN | Maintain | Buy (N/A) |
|
Details | ||
| 1/29/2026 | Lantheus Holdings | LNTH | Maintain | Buy (N/A) |
|
Details | ||
| 1/29/2026 | Geron Corporation | GERN | Maintain | Buy (N/A) |
|
Details | ||
| 1/13/2026 | Day One Biopharmaceuticals | DAWN | New Coverage | Buy (N/A) |
11.33 (12.78) |
12.8% | Details | |
| 12/30/2025 | Lantheus Holdings | LNTH | Maintain | Buy (N/A) |
|
Details | ||
| 12/19/2025 | EyePoint Inc. | EYPT | New Coverage | Buy (N/A) |
16.66 (15.75) |
-5.46% | Details | |
| 12/19/2025 | Rocket Pharmaceuticals | RCKT | New Coverage | Hold (N/A) |
3.27 (4.41) |
34.86% | Details | |
| 12/16/2025 | Ocular Therapeutix | OCUL | Maintain | Buy (N/A) |
|
Details | ||
| 11/7/2025 | Protagonist Therapeutics | PTGX | Maintain | (N/A) |
|
Details | ||
| 10/30/2025 | Ocular Therapeutix | OCUL | Maintain | Buy (N/A) |
|
Details | ||
| 9/15/2025 | Lantheus Holdings | LNTH | Maintain | Buy (N/A) |
|
Details | ||
| 8/14/2025 | UroGen Pharma | URGN | Maintain | Buy (N/A) |
|
Details | ||
| 8/7/2025 | Vaxcyte | PCVX | Maintain | Buy (N/A) |
|
Details | ||
| 8/5/2025 | Ocular Therapeutix | OCUL | Maintain | Buy (N/A) |
|
Details | ||
| 7/9/2025 | Verona Pharma | VRNA | Downgrade | Hold (Buy) |
86.86 (106.91) |
23.08% | Details | |
| 5/12/2025 | Day One Biopharmaceuticals | DAWN | Maintain | Buy (N/A) |
|
Details | ||
| 4/28/2025 | Verona Pharma | VRNA | New Coverage | Buy (N/A) |
65.46 (86.86) |
32.69% | Details | |
| 4/23/2025 | Geron Corporation | GERN | Maintain | Buy (N/A) |
|
Details | ||
| 3/3/2025 | Protagonist Therapeutics | PTGX | Maintain | Buy (N/A) |
|
Details | ||
| 2/27/2025 | Disc Medicine | IRON | New Coverage | Buy (N/A) |
54.46 (61.18) |
12.34% | Details | |
| 2/26/2025 | Geron Corporation | GERN | Maintain | Buy (N/A) |
|
Details | ||
| 11/11/2024 | Lantheus Holdings | LNTH | Maintain | Buy (N/A) |
|
Details | ||
| 10/29/2024 | TG Therapeutics | TGTX | New Coverage | Buy (N/A) |
24.35 (29.27) |
20.21% | Details | |
| 10/14/2024 | Protagonist Therapeutics | PTGX | Maintain | Buy (N/A) |
|
Details | ||
| 10/10/2024 | Vaxcyte | PCVX | Maintain | Buy (N/A) |
|
Details | ||
| 9/24/2024 | Protagonist Therapeutics | PTGX | New Coverage | Buy (N/A) |
46.15 (92.09) |
99.54% | Details | |
| 9/16/2024 | Sutro Biopharma | STRO | Maintain | Buy (N/A) |
|
Details | ||
| 9/16/2024 | Lantheus Holdings | LNTH | Maintain | Buy (N/A) |
|
Details | ||
| 9/16/2024 | Bicycle Therapeutics | BCYC | Maintain | Buy (N/A) |
|
Details | ||
| 9/3/2024 | Vaxcyte | PCVX | Maintain | Buy (N/A) |
|
Details | ||
| 8/14/2024 | Sutro Biopharma | STRO | Maintain | Buy (N/A) |
|
Details | ||
| 8/13/2024 | UroGen Pharma | URGN | Maintain | Buy (N/A) |
|
Details | ||
| 7/23/2024 | UroGen Pharma | URGN | Maintain | Buy (N/A) |
|
Details | ||
| 7/23/2024 | Lantheus Holdings | LNTH | Maintain | Buy (N/A) |
|
Details | ||
| 7/1/2024 | Vaxcyte | PCVX | Maintain | Buy (N/A) |
|
Details | ||
| 6/20/2024 | Ocular Therapeutix | OCUL | Upgrade | Buy (Hold) |
5.49 (10.27) |
87.07% | Details | |
| 6/14/2024 | Ocular Therapeutix | OCUL | Maintain | Hold (N/A) |
|
Details | ||
| 6/13/2024 | UroGen Pharma | URGN | Maintain | Buy (N/A) |
|
Details | ||
| 6/7/2024 | Geron Corporation | GERN | Maintain | Buy (N/A) |
|
Details | ||
| 6/3/2024 | Merus N.V. | MRUS | Maintain | Buy (N/A) |
|
Details | ||
| 5/29/2024 | Ikena Oconology | IKNA | Maintain | Buy (N/A) |
|
Details | ||
| 5/28/2024 | Merus N.V. | MRUS | Maintain | Buy (N/A) |
|
Details | ||
| 5/24/2024 | Merus N.V. | MRUS | Maintain | Buy (N/A) |
|
Details | ||
| 5/8/2024 | Ocular Therapeutix | OCUL | Maintain | Hold (N/A) |
|
Details | ||
| 4/29/2024 | Geron Corporation | GERN | New Coverage | Buy (N/A) |
3.79 (1.53) |
-59.63% | Details | |
| 1/16/2024 | Harpoon Therapeutics | HARP | Downgrade | Hold (Buy) |
22.45 (23.01) |
2.49% | Details | |
| 11/20/2023 | Harpoon Therapeutics | HARP | New Coverage | Buy (N/A) |
11.41 (23.01) |
101.67% | Details | |
| 8/21/2023 | Merus N.V. | MRUS | New Coverage | Buy (N/A) |
21.09 (90.00) |
326.74% | Details | |
| 8/31/2022 | Bicycle Therapeutics | BCYC | New Coverage | Buy (N/A) |
25.37 (5.19) |
-79.54% | Details |
